International practice heterogeneity in pre‐transplant management of pulmonary hypertension related to pediatric left heart disease

Abstract

AbstractBackgroundElevated pulmonary vascular resistance (PVR) in the setting of left heart failure may contribute to poor outcomes after pediatric heart transplant (HTx), but peri‐transplant management is variable.MethodsWe sought to characterize international practice by surveying physicians at pediatric HTx centers.ResultsWe received 49 complete responses from 39 centers in 16 countries. Most respondents are pediatric cardiologists (90%), practice at centers offering heart (86%) and lung (55%) transplant, and perform pre‐HTx acute vasoreactivity testing (AVT, 88%) in patients with elevated PVR. Half (51%) reported defining a PVR cutoff for HTx eligibility as ≤6 WU m2 (56%) post‐AVT (84%). The highest post‐AVT PVR ever accepted for HTx ranged from 3–14.4 (median 6) WU m2. To treat elevated pre‐transplant PVR, phosphodiesterase type 5 inhibitors are most common (65%) followed by oxygen (31%), nitric oxide (14%), endothelin receptor antagonists (11%), and prostacyclins (6%). Nearly a third (31%) do not routinely use pulmonary vasodilators without implantation of a left ventricular assist device (LVAD). Case scenarios highlight treatment variability: in a restrictive cardiomyopathy scenario, HTx listing with post‐transplant vasodilator therapy was favored, whereas in a Shone's complex patient with fixed PVR, LVAD ± pulmonary vasodilators followed by repeat catheterization was most common. Management of dilated cardiomyopathy with reactive PVR was variable. Most continue vasodilator therapy until HTx (16%), PVR normalizes (16%) or ≤6 months.ConclusionsManagement of elevated PVR in children awaiting HTx is heterogenous. Evidence‐based guidelines are needed to allow for longitudinal determination of optimal outcomes and standardized care.